University of Florence
Infants with HIV-1 benefit from early combined antiretroviral therapy
Published in AIDS Weekly and Law, March 30th, 2006
Researchers in Italy conducted a study "to investigate the impact of early versus deferred combined antiretroviral treatment (ART) in asymptomatic or moderately symptomatic [Centers for Disease Control and Prevention (CDC) category N, A, or B] infants with perinatal HIV-1 infection."
Elena Chiappini at the University of Florence and collaborators explained, "A multicenter nationwide case-control study was conducted. Data from 30 infants treated with combined ART with three or more drugs before six months of age were compared with data from 103 infants starting...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
Source: AIDS Weekly and Law (2006-03-30)
More Articles from AIDS Weekly and Law
- CytoDyn, Inc.
CytoDyn gets green light for China joint venture - Fiocruz MS, Rio de Janeiro
Advanced HIV cases suggest large pool of undiagnosed HIV infections in Southeast Brazil - Jewish General Hospital, Montreal
Data advance knowledge in HIV/AIDS pathogenesis research - Millenia Hope Inc.
Millenia Hope acquires pending patent describing compounds that inhibit HIV-1 RNase_H - U.S. National Institutes of Health
Cancer risk increased among HIV-infected persons in Uganda - Albert Einstein College of Medicine, Bronx
HIV knowledge lower among sexually inexperienced youth - More from this issue of AIDS Weekly and Law
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
